SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Kronos Bio, Inc. Announces First Patient Dosed in AGILITY Phase 3 Clinical Trial of Entospletinib in Patients With Newly Diagnosed NPM1-mutated Acute Myeloid Leukemia

12/06/2021 | 07:00am EDT

Kronos Bio, Inc. announced that the first patient has been dosed in the registrational Phase 3 AGILITY clinical trial of entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK), in combination with standard of care anthracycline and cytarabine (7+3) chemotherapy. This trial is the first in acute myeloid leukemia (AML) to use measurable residual disease (MRD) as the primary endpoint and has the potential to support accelerated approval of entospletinib by the U.S. Food and Drug Administration (FDA) as a treatment for patients newly diagnosed with NPM1-mutated AML who are fit for intensive induction. Entospletinib is Kronos Bio?s lead product candidate, and the company expects to share data from the trial in the second half of 2023. The randomized, double-blind, placebo-controlled trial is designed to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in approximately 180 adults who have been newly diagnosed with NPM1-mutated AML. This trial will test the hypothesis, based on robust preclinical and Phase 2 clinical data, that NPM1 mutation leads to dependency on SYK signaling. The NPM1 mutation is present in about 30% of all adult patients with AML. The primary endpoint of the trial is MRD negative complete response (CR), as measured by molecular detection of mutant NPM1 alleles in bone marrow, which affords a high degree of sensitivity to detect MRD. Numerous clinical studies have shown that patients with NPM1 mutations who achieve MRD negative CR after induction chemotherapy survive longer than patients who achieve CR but have detectable MRD. If successful, this would be the first time MRD is used as the basis for seeking accelerated approval in AML. The decision to proceed with this trial design was made after an End-of-Phase 2 discussion with the FDA. In the trial, patients will be randomized 1:1 to receive either entospletinib or placebo in combination with standard induction and consolidation chemotherapy. Remission and MRD status will be assessed after the first two cycles of chemotherapy and patients may receive up to a total of five cycles. Event-free survival (EFS) is a key secondary endpoint, and mature EFS data will potentially be used to support full approval. Kronos Bio acquired entospletinib and another SYK inhibitor, lanraplenib, from Gilead Sciences in July 2020. As previously announced, under the agreement with Gilead, the initiation of the Phase 3 trial triggers a $29 million milestone payment from Kronos Bio to Gilead. The payment will be recorded in the fourth quarter. Lanraplenib is being developed for the treatment of patients with relapsed/refractory FLT3-mutated AML and patients newly diagnosed with NPM1-mutated and/or? FLT3-mutated AML ?who are older than 75 years old or are not eligible for intensive induction chemotherapy.

© S&P Capital IQ 2021
All news about KRONOS BIO, INC.
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
05/17Kronos Bio Announces Participation in H.C. Wainwright Global Investment Conference
05/12Kronos Bio to Feature Entospletinib, Lanraplenib Investigational Inhibitors at European..
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
05/12Kronos Bio's Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Feature..
05/04Kronos Bio Reports Recent Business Progress and First-Quarter 2022 Financial Results
05/04Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
04/21KRONOS BIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
04/08Kronos Bio Says Preclinical Data Shows Potential for Its Treatment of Certain Cancer Ty..
More news
Analyst Recommendations on KRONOS BIO, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -155 M - -
Net cash 2022 72,8 M - -
P/E ratio 2022 -1,31x
Yield 2022 -
Capitalization 213 M 213 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 96
Free-Float 85,5%
Duration : Period :
Kronos Bio, Inc. Technical Analysis Chart | KRON | US50107A1043 | MarketScreener
Technical analysis trends KRONOS BIO, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 4
Last Close Price 3,76 $
Average target price 29,50 $
Spread / Average Target 685%
EPS Revisions
Managers and Directors
Norbert W. Bischofberger President, Chief Executive Officer & Director
Yasir B. Al-Wakeel CFO & Head-Corporate Development
Arie S. Belldegrun Chairman
Jorge DiMartino Chief Medical Officer & EVP-Clinical Development
Christopher Dinsmore Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
KRONOS BIO, INC.-72.33%213
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323